Ambani Orgochem

Quick check

The five things to look at first. Open one for more.

• DebtModerate debtIt owes ₹78 Cr against ₹63 Cr of shareholders' money (Sep 2026), 1.24 times.
• ResultsGrowingIn the Sep 2026 quarter, sales rose 109% and profit rose 250% from a year earlier. (A year earlier it made a loss.)
• DilutionHeavy dilutionIssued 12.6 lakh new shares in the last year (+18%), raising ₹8.51 Cr.
• PromotersPromoters sellingThe promoters (founders or parent) own 53%, down from 61% in Mar 2025.
• ValuationNormal for this stockThe share trades at 36.5 times its yearly earnings (P/E), cheaper than 67% of the time in the last 5 years. Its usual P/E is about 33.

Ambani Orgochem against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)36.5 against a typical 26.3: pricier than most peers (1st = cheapest).88th of 129
• Sales growth+108.5% against a typical +25.9% from a year earlier.8th of 112
• Share price, 3 months+45.6% against a typical −5.5%.9th of 118
• Size₹ 126.6 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).87th of 126

Exchange filings and their impact on the company.

• 27 Oct 2026Issue of SecuritiesHigh impactPositivePrice +0.7% on 28 Oct
  Board approves Rs 43.9 cr promoter-backed warrants to fund expansion, sharply boosting net worth despite dilution.

  Ambani Orgochem plans to issue up to 43.92 lakh convertible warrants at Rs 100 each to raise up to Rs 43.9 crore from 9 promoter and public allottees. Each warrant converts into one Rs 10 equity share, subject to stock exchange approval. The money will boost net worth by about 78% and is expected to fund capacity expansion and strengthen the balance sheet, though it will dilute existing shares by about 37% on full conversion.

  Full analysisFiling
• 26 Oct 2026General UpdatesHigh impactVery positivePrice −3.2% on 27 Oct
  H1 FY27 revenue up 55% and profit up 18x signals ~45% full-year growth with major capacity doubling ahead.

  Ambani Orgochem shared its H1 FY27 investor presentation reporting revenue of Rs 171.22 crore, up 54.87% from last year, EBITDA of Rs 11.32 crore, up 43%, and net profit of Rs 3.45 crore versus Rs 0.19 crore last year with EPS of Rs 4.02. The company highlighted 50,000 MT annual capacity across 4 plants and expansions including acrylic coatings from 2,000 to 4,500 tonnes per month and salicylic acid from 50 to 200 tonnes per month, plus 5 new peroxides and 12+ salicylates under development. The strong half-year and capacity build-out point to much higher sales and profits as new capacity ramps up.

  Full analysisFiling
• 15 Oct 2026Outcome of Board MeetingHigh impactVery positivePrice +5% on 16 Oct
  H1 revenue up 55% and profit up 17x with Rs 8.5 cr warrant equity raised and Rs 8.2 cr insurance claim confirmed.

  Ambani Orgochem reported strong H1 FY27 results with revenue of Rs 171.2 crore, up 55% from Rs 110.6 crore last year, and net profit of Rs 3.41 crore versus Rs 0.20 crore. The surveyor assessed the Dahej fire loss-of-profit insurance claim at Rs 8.18 crore, of which Rs 0.68 crore extra was booked this half, expected within six months. The company also converted 12.6 lakh warrants into shares raising Rs 8.51 crore and redeemed Rs 4.55 crore of preference shares while investing Rs 8.69 crore in fixed assets.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Apooni Rakesh Shah

Whole Time Chairman of the Board

Paresh Harsuklal Shah

Chief Executive Officer

Bhavesh Babulal Pandya

Chief Financial Officer

Vaanie Dangi

Compliance Officer, Company Secretary

Rakesh Hasmukhlal Shah

Managing Director, Executive Director